Clinical Trials Logo

Advanced Cancers clinical trials

View clinical trials related to Advanced Cancers.

Filter by:

NCT ID: NCT00877773 Terminated - Advanced Cancers Clinical Trials

Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients

Start date: April 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if temsirolimus can help to control advanced cancer in patients who also have a PI3K mutation and/or PTEN loss. The safety of this drug will also be tested.

NCT ID: NCT00836927 Terminated - Advanced Cancers Clinical Trials

Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038)

Start date: February 1, 2009
Phase: Phase 2
Study type: Interventional

To describe the long-term safety of deforolimus (ridaforolimus, MK-8669) in participants for whom a clinical benefit has been established in a prior parent trial (MK-8669-013, NCT00060645; MK-8669-016, NCT00112372; and MK-8669-028, NCT00704054) with deforolimus and/or in those who remain in long-term follow-up.

NCT ID: NCT00499382 Terminated - Advanced Cancers Clinical Trials

Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging

Start date: September 2004
Phase: N/A
Study type: Observational

Primary Objective: - Evaluate the agreement between radionuclide ventriculography (RNV) and gated F-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) in calculating left ventricular ejection fraction (LVEF), end diastolic volume (EDV) and end systolic volume (ESV).